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ABSTRACT: Biomarkers have the potential to play important
roles in diagnosis and in the identification of patient populations
that could benefit from targeted therapy. They also serve as mark-
ers of drug efficacy and could be used to monitor treatment effec-
tiveness, drug toxicity, and development of resistance. One
example of a successful biomarker development is represented
by the testing for Her-2/ERB2 over expression. Tissue sampling
is crucial for the definition and validation of new biomarkers. In
general, biomarker and its corresponding assay must be validated
before phase III to be useful in reducing trial size.
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For next-generation therapies drug development by chance is
moving toward cancer therapies that are molecularly targeted.
Nevertheless, drug development still relies on the same basic
strategies used for cytotoxic drugs. In the new era of cancer treat-
ment, instead of applying the concept of maximum tolerated
dose (MTD) as does cytotoxic drug therapy, we must think in
terms of the optimal biologically active dose (OBAD) and, perhaps,
the maximum tolerated economic cost. Only administration of
molecularly targeted drugs at OBAD can demonstrate their opti-
mum therapeutic efficacy.
Biomarkers could play important roles in disease diagnosis
and in the identification of patient populations that could benefit
from targeted therapy. They also serve as markers of drug efficacy
and could be used to monitor treatment effectiveness, drug toxic-
ity, and development of resistance. Moreover, some biomarkers
appear to be surrogates for clinical benefit; as such, they have
the potential to serve as endpoints in clinical trials. To use bio-
markers to maximum advantage, several scientific hurdles must
be surmounted. For example, a need exists to differentiate molec-
ular and therapeutic targets, determine which targets to block to
achieve tumour control, overcome resistance mechanisms, and
identify patients who need treatment and are potential
responders.
Many techniques – genomics, proteomics, interactomics,
peptidomics, and degradomics – offer a spectrum of analytical
possibilities. In the early days, procedures involved removing
most proteins, e.g. albumin, prior to analysis. That approach,
unfortunately, eliminates the opportunity to investigate inter-
actomics involving the small peptides bound to large molecules.
To identify potential biomarkers and study their roles in the dis-
ease pathway, it is necessary to look for small molecules in serum
(peptidomics) as well as protein-degradation products (degrado-
mics). Many peptides have excellent cancer signatures. Reverse-
phase protein microarray provides a map of known cell-signalling
proteins.1
Biomarker development should follow different pathways
depending on the stage of drug development. For early stages of
clinical development, biomarkers can identify or confirm molecu-
lar targets, help optimise dose schedules for the anticancer agent,
and might correlate with clinical benefit. Identifying clinically rel-
evant targets is challenging; in numerous examples, the intended
target was found to be irrelevant. As not all molecular targets are
legitimate therapeutic targets, however, biomarkers can provide a
means of determining which target(s), when inhibited, correlate
with tumour control. In the case of some anticancer agents
(e.g. cetuximab, gefitinib, farnesyl transferase inhibitors, and
inhibitors of vascular endothelial growth factor [VEGF]), it appears
that the original molecular target is not the only therapeutic
target.
In the later stages of clinical development, identified markers
could be used to select the patients most likely to respond to the
targeted agent. Any biomarker used as a basis for patient selec-
tion must demonstrate excellent sensitivity and specificity; other-
wise, the risk of not treating patients who might benefit would be
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unacceptably high. Identified biomarkers could also be a basis for
monitoring treatment and identifying resistance mechanisms.
One example for the need to identify biomarkers is immuno-
therapy. It is important to bear in mind that immune-mediated
anti-tumour reactivity is the result of a well-orchestrated interac-
tion of multiple factors and multiple pathways. Redundant path-
ways and interactions present a set of challenges when designing
immunotherapies or identifying surrogates. Studying any of the
multiple immune mediators in isolation offers little about efficacy
because of these interactions. Therefore a set of biomarkers is
expected to more and more replace single ones. Methods such
as proteomics need to be better standardised and validated as
they may speed up the identification of biomarkers and thus drug
development as a whole.
As soon as biomarkers have been fully validated, they have
the potential to be developed to surrogate markers. Surrogate
endpoints should be based on functional parameters of critical
importance for cancer control. Although functional parameter
techniques have been around for many years, they can provide
very useful information for molecularly targeted drug develop-
ment. Such parameters include cell proliferation, cell death,
inflammatory infiltration, and tumour regression.
For example, the immediate preoperative anastrozole, tamox-
ifen, or combined with tamoxifen (IMPACT) trial relied upon a
measure of proliferation – immunohistochemical assessment of
the nuclear antigen Ki-67 – as an endpoint.2,3 The method was
highly reproducible and predictive of therapeutic efficacy. Mohsin
et al.4 used another functional parameter – apoptosis – in a trial of
the neoadjuvant trastuzumab in 35 patients with locally
advanced Her-2/neu overexpressing breast cancers. They found
that induction of apoptosis correlated with tumour regression.
Tumour biopsies can be examined for inflammatory lympho-
cyte migration as another means of monitoring treatment effi-
cacy using functional parameters, as shown in one study
involving stage III melanoma patients treated with interferon-
alpha.5 Patients whose tumours demonstrated P2% CD4+
tumour-infiltrating lymphocytes (TIL’s) had prolonged time to
progression and improved overall survival compared with
patients whose tumours had < 2% TIL’s. Finally, tumour regressive
changes correlate with long-term survival. Overall survival in
metastatic melanoma patients has been shown to correlate with
tumour regressive changes.6
Trials that rely on functional parameter endpoints obviously
depend on the availability of tumour biopsies. Obtaining such
samples is critical for developing molecularly targeted therapies.
Stated otherwise, ‘No tissue – no trial’.7 For example, with biopsy
specimens, it would be possible to compare all phosphorylated
proteins in the tumours before and after treatment to observe
potential changes. Moreover, it is becoming more possible to pre-
dict response to immunotherapy based on tumour biopsies.
Therefore prognostic biomarkers also provide means for identify-
ing patients who might be at high risk of disease recurrence after
radical surgery and might be candidates for adjuvant therapy.
Predictive biomarkers could be used to discern which patients
would be more likely to respond to a particular therapy. Interleu-
kin-6 (IL-6) production by peripheral blood mononuclear cells
(PBMC’s) preoperatively collected from patients with primary
colorectal cancer predicts survival. Eight of 13 patients with
>5000 pg/mL IL-6 died from cancer within the 54-month follow-
up period, whereas no cancer-related deaths were recorded
among 21 patients with 5000 pg/mL IL-6 or less. A multivariate
Cox regression analysis, stratified for tumour and node stage,
identified IL-6 production as an independent prognostic factor.8
In conclusion, molecularly targeted treatment of cancer is
sometimes criticised for poor therapeutic efficacy. Among the
reasons that it has not met with greater success are reliance upon
suboptimal dosing, the fact that molecular targets are not always
the therapeutic target, pathway redundancy, and resistance
mechanisms. However, molecularly targeted treatment of cancer
is still at a very early stage; there is a great need to identify rele-
vant therapeutic targets and establish molecular and functional
surrogate endpoints. The techniques are available the time to
design the respective clinical trials is now.
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